Eflapegrastim

Eflapegrastim
Names
Trade namesRolvedon
Other namesEflapegrastim-xnst, HM-10460A, SPI-2012
Clinical data
Drug classGranulocyte colony-stimulating factor (G-CSF)[1]
Main usesReduce the risk of febrile neutropenia with chemotherapy[1]
Side effectsTiredness, nausea, diarrhea, pain, fever, rash, low red blood cells[1]
Routes of
use		Subcutaneous
Typical dose13.2 mg[1]
External links
AHFS/Drugs.comMonograph
Legal
License data
Legal status

Eflapegrastim, sold under the brand names Rolvedon, is a medication used to reduce the risk of febrile neutropenia in non-myeloid cancers receiving chemotherapy that results in bone marrow suppression.[1] It is given by injection under the skin.[1] It is given about 24 hours after chemotherapy.[1]

Common side effects include tiredness, nausea, diarrhea, pain, fever, rash, and low red cells.[1] Other side effects may include spleen rupture, ARDS, anaphylaxis, low platelets, glomerulonephritis, and myelodysplastic syndrome.[1] It is a granulocyte colony-stimulating factor (G-CSF), specifically a leukocyte growth factor.[1]

Eflapegrastim was approved for medical use in the United States in 2022.[1] It is not approved in Europe or the United Kingdom as of 2022.[2] It costs about 4,700 USD per dose in the United States as of 2022.[3]

Medical uses

Eflapegrastim is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adults with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia.[1]

Its efficacy has been shown to be non-inferior to pegfilgrastim.[1]

Dosage

It is generally given at a dose of 13.2 mg once per chemotherapy cycle.[1]

Mechanism of action

Mechanism of Eflapegrastim[4]

In terms of the mode of action for Eflapegrastim we find that it is a rhG-CSF, which binds to G-CSF receptors on myeloid progenitor cells,as well as neutrophils. This in turn causes signaling pathways to adjust neutrophil differentiation, and survival, which ultimately sees more white blood cell production[4]

References

  1. ↑ 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 1.12 1.13 1.14 "Rolvedon- eflapegrastim-xnst injection, solution". DailyMed. 23 September 2022. Archived from the original on 16 October 2022. Retrieved 16 October 2022.
  2. ↑ "Eflapegrastim". SPS - Specialist Pharmacy Service. 16 March 2018. Archived from the original on 25 June 2022. Retrieved 13 December 2022.
  3. ↑ "Rolvedon Prices, Coupons, Copay & Patient Assistance". Drugs.com. Retrieved 13 December 2022.
  4. ↑ 4.0 4.1 Theyab, Abdulrahman; Alsharif, Khalaf F.; Alzahrani, Khalid J.; Oyouni, Atif Abdulwahab A.; Hawsawi, Yousef MohammedRabaa; Algahtani, Mohammad; Alghamdi, Saad; Alshammary, Amal F. (5 January 2023). "New insight into strategies used to develop long-acting G-CSF biologics for neutropenia therapy". Frontiers in Oncology. 12. doi:10.3389/fonc.2022.1026377.{{cite journal}}: CS1 maint: unflagged free DOI (link)

External links

External sites:
Identifiers:
  • Clinical trial number NCT02643420 for "SPI-2012 vs Pegfilgrastim in the Management of Neutropenia in Participants With Breast Cancer With Docetaxel and Cyclophosphamide (ADVANCE) (ADVANCE)" at ClinicalTrials.gov
  • Clinical trial number NCT02953340 for "SPI-2012 vs Pegfilgrastim in Management of Neutropenia in Breast Cancer Participants With Docetaxel and Cyclophosphamide" at ClinicalTrials.gov

This article is issued from WikiProjectMed. The text is available under Creative Commons Attribution-ShareAlike License unless otherwise noted. Additional terms may apply for the media files.